News | May 13, 2009

Cancer Biotherapy Market Could Reach $60B in 10 Years

May 13, 2009 - The biotherapies for cancer treatment may become a $60 billion market in 10 years, doubling in the next five years, according to a new report by Kalorama Information, “World Market for Cancer Therapeutics and Biotherapeutics, 3rd Edition.”

The report found that the biotherapy segment has recorded a 34.1 percent annual growth rate since 2004 and is forecast to nearly double by 2013.

With sales of $24.5 billion in 2008, biologics currently represents about half of the total cancer treatment market, but Kalorama expects its market share to increase to 60 percent by 2013.

“The future looks bright for biological cancer treatments,” said Melissa Elder, an analyst for Kalorama. “With many highly unpleasant and often dangerous side effects from traditional cancer treatments, the potential for targeted biologic therapies that help the body target malignant tumors while leaving healthy tissue intact offers hope to millions of suffering cancer patients.”

Several factors continue to fuel double-digit growth in biotherapeutics, including their success as a safer, more effective cancer therapy, the rising incidence of cancer and the increased cost for newly approved therapies in the biological area.

As the benefits of biologic products continue to be recognized, competition will likely intensify. Existing products will continue to lead the segment, the report stated, though innovative new products will display healthy growth and create new competition. The leading competitors in this market are limited to a handful of marketers, including Roche, Novartis, Bristol-Myers Squibb and Pfizer.

Biotherapeutics includes monoclonal antibodies, interleukins/interferons and kinases and other biotherapies. Monoclonal antibodies represent the lion’s share of this market, but the highest growth has been and will continue to be in the kinases and other biotherapy segments where several new approvals have contributed to phenomenal annual growth.

Source: www.healthcarefinancenews.com

Related Content

Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introd
Sam Hancock, Ph.D.

Sam Hancock, Ph.D.

Sponsored Content | Case Study | Radiation Oncology | November 06, 2017
In establishing the new Southeast Cancer Center (Cape Girardeau, Mo.), clinic officials not only had the opportunity to...
Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Feature | Proton Therapy | November 06, 2017 | By Larisa Brass, MPH
Thirty-three. Twenty-nine. Sixty-four. These are the ages of the breast cancer patients who have walked through the...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
Videos | Women's Health | October 23, 2017
William Hall, M.D., radiation oncologist in the Department of Radiation Oncology at PeaceHealth St. Joseph Medical...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" was presented by Parag P
Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
The forthcoming RayCare OIS from RaySearch will be web-based to more easily connect all members of the patient care team throughout a comprehensive cancer center

The forthcoming RayCare OIS from RaySearch will be web-based to more easily connect all members of the patient care team throughout a comprehensive cancer center.

Feature | Oncology Information Management Systems (OIMS) | September 08, 2017 | By Jeff Zagoudis
Cancer is perhaps the most highly personal, complex disease in our world today.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...
Overlay Init